Context Therapeutics Inc. Files 8-K
Ticker: CNTX · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1842952
| Field | Detail |
|---|---|
| Company | Context Therapeutics Inc. (CNTX) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: CTX
TL;DR
CTX shares unchanged as Context Therapeutics files routine 8-K with updated corporate info.
AI Summary
Context Therapeutics Inc. filed an 8-K on January 14, 2025, reporting on various events and financial statements. The filing indicates the company's principal executive offices are located at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103, with a phone number of (267) 225-7416. The company was formerly known as Context Therapeutics LLC until January 28, 2021.
Why It Matters
This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Context Therapeutics Inc.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Context Therapeutics Inc. (company) — Registrant
- January 14, 2025 (date) — Date of earliest event reported
- 2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103 (address) — Principal executive offices
- (267) 225-7416 (phone_number) — Registrant's telephone number
- Context Therapeutics LLC (company) — Former name
- January 28, 2021 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing for Context Therapeutics Inc.?
The primary purpose is to report on various corporate events and provide updated information, including the date of the earliest event reported as January 14, 2025.
Where are Context Therapeutics Inc.'s principal executive offices located?
The principal executive offices are located at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103.
What was the former name of Context Therapeutics Inc.?
The former name of Context Therapeutics Inc. was Context Therapeutics LLC.
When did the company change its name from Context Therapeutics LLC?
The company changed its name from Context Therapeutics LLC on January 28, 2021.
What is the telephone number for Context Therapeutics Inc.?
The telephone number for Context Therapeutics Inc. is (267) 225-7416.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-01-14 17:03:03
Key Financial Figures
- $0.001 — mon Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check
Filing Documents
- cntx-20250114.htm (8-K) — 25KB
- a20250114-firstpatientdose.htm (EX-99.1) — 11KB
- image_0.jpg (GRAPHIC) — 193KB
- 0001842952-25-000006.txt ( ) — 437KB
- cntx-20250114.xsd (EX-101.SCH) — 2KB
- cntx-20250114_lab.xml (EX-101.LAB) — 24KB
- cntx-20250114_pre.xml (EX-101.PRE) — 14KB
- cntx-20250114_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On January 14, 2025, Context Therapeutics Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Company's Phase 1 clinical trial evaluating CTIM-76. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.
01. Other Events
Item 8.01. Other Events. On January 14, 2025, the Company announced that the first patient has been dosed in the Company's Phase 1 clinical trial evaluating CTIM-76. The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. ( d) Exhibits Exhibit No. Description 99.1 Press Release issued by Context Therapeutics Inc., dated January 14, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 14, 2025 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer